Thursday, July 24, 2025 2:51:03 PM
Doc, while I agree with you, I don't expect NWBO to say anything until something official comes out of the UK. While I believe it's looking like the EDEN is now a part of the total package, we'll only know that for certain when something official is announced from the UK.
If in fact the EDEN is included, it's also very possible that it's what's holding up the approval. As I see it, it's not an essential part of the approval if the label is just for GBM as the 20 tiny cleanrooms should meet the initial demand, but if the label is to be tumor agnostic, then they'd be totally overwhelmed without the EDEN.
I certainly don't know that I'll be proven right, but I still believe the hints coming out of the UK say that it's all going to be in the package. If it is, then the question becomes, were the other regulators involved, and is this truly going to be a multi-national approval?
I'm not saying this is the case, but if it were, I suspect a 100 banger this year, or sooner, is not out of the picture from todays prices.
Gary
If in fact the EDEN is included, it's also very possible that it's what's holding up the approval. As I see it, it's not an essential part of the approval if the label is just for GBM as the 20 tiny cleanrooms should meet the initial demand, but if the label is to be tumor agnostic, then they'd be totally overwhelmed without the EDEN.
I certainly don't know that I'll be proven right, but I still believe the hints coming out of the UK say that it's all going to be in the package. If it is, then the question becomes, were the other regulators involved, and is this truly going to be a multi-national approval?
I'm not saying this is the case, but if it were, I suspect a 100 banger this year, or sooner, is not out of the picture from todays prices.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
